Litigation Details for Aragon Pharmaceuticals, Inc. v. Eugia Pharma Specialities Limited (D. Del. 2022)

Aragon Pharmaceuticals, Inc. v. Eugia Pharma Specialities Limited (D. Del. 2022)

Docket		Date Filed	2022-05-26
Court	District Court, D. Delaware	Date Terminated	2022-09-07
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	8,445,507; 8,802,689; 9,388,159; 9,481,663; 9,987,261
Link to Docket	External link to docket

Details for Aragon Pharmaceuticals, Inc. v. Eugia Pharma Specialities Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
0000-00-00				External link to document
2022-05-26	1	Complaint	of United States Patent Nos. 8,445,507 (“the 507 Patent”), 8,802,689 (“the 689 Patent”), 9,388,159 (“the…“the 159 Patent”), 9,481,663 (“the 663 Patent”), and 9,987,261 (“the 261 Patent”) (collectively, the …11. This is an action for patent infringement arising under the Patent Laws of the United States, … THE PATENTS-IN-SUIT 46. On May 21, 2013, the 507 Patent, titled “Androgen Receptor…of the 689 Patent is attached as Exhibit B. 48. On July 12, 2016, the 159 Patent, titled “Substituted	External link to document
2022-09-08	19	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,445,507 B2; 8,802,689 B2; 9,388,159… 7 September 2022 1:22-cv-00688 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2022-05-26	3	ANDA Form	Expiration of Patent: U.S. Patent No. 8,445,507 expires on September 15, 2030; U.S. Patent Nos. 8,802,689… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) …and 9,987,261 expire on March 27, 2027; and U.S. Patent No. 9,481,663 expires on June 4, 2033. Thirty Month… 7 September 2022 1:22-cv-00688 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document